As many biotechnology companies struggle to progress pipelines and deal with product setbacks in the face of dwindling cash reserves, Europe's vaccines plays are navigating today's difficult waters more successfully.
Vaccine companies, the perennial middle child of the life sciences, have increased margins on their products, consolidated effectively, jettisoned dead...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?